Bland-Altman plot of the final model with observed and predicted EQ-5D-3L values.

Bland-Altman plot of the final model with observed and predicted EQ-5D-3L values.</p

Summary results of the regression models.

Summary results of the regression models.</p

Characteristics of the final model (Model 1d) without shrinkage.

Characteristics of the final model (Model 1d) without shrinkage.</p

Mirrored histogram of observed and predicted EQ-5D-3L values.

Mirrored histogram of observed and predicted EQ-5D-3L values.</p

Patient, tumor and treatment characteristics.

Tumors were staged according to cTNM clinical classification of the Union for International Cancer Control (UICC) (2009, 7th edition) [24].</p

Summary results of HRQoL data derived from 361 observations.

Summary results of HRQoL data derived from 361 observations.</p

Flowchart of model development.

The grey rectangles display the three predictor sets with their criteria; the white rectangles the different models. The squares indicate the assessment of the models during model comparison; the rhombuses indicate the decision-making in the process. Assessment of the model performance is displayed with a dotted line. The EORTC QLQ-C30 and QLQ-H&N35 scales included in the predictor sets are highlighted in grey circles. The scales that were excluded are colored white. Abbreviations: AL, appetite loss; Cough, coughing; CF, cognitive functioning; CP, constipation; DH, diarrhea; DP, dyspnea; DM, dry mouth; EF, emotional functioning; EORTC, European Organization for Research and Treatment of Cancer; EQ-5D-3L, three-level EuroQol five-dimensional questionnaire; FD, financial difficulties; FG, fatigue; FI, felt ill; FT, feeding tube; GHS/QoL, global health status/quality of life; HRQoL, health-related quality of life; IS, insomnia; LS, less sexuality; NT, nutritional supplements; NV, nausea and vomiting; OLS, ordinary least-squares, OM, opening mouth; PF, physical functioning; PK, pain killers; Quality of Life Questionnaire-Core 30; QLQ-H&N35, Quality of Life Questionnaire-Head and Neck35; RF, role functioning; SC, trouble with social contact; SE, trouble with social eating; SpP, speech problems; SeP, senses problems; SL, swallowing; SF, social functioning; SS, sticky saliva; WG, weight gain; WL, weight loss.</p

Supplementary Table S1 from Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer

Table S1. Participating institutions for all patients (N=345) and patients presenting with anemia(N=54).</p

Supplementary Table S2 from Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer

Table S2. Eligibility criteria.</p

Supplementary Table S3 from Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer

Table S3. Treatment delivery for all patients (N=345) and the patients presenting with anemia (N=54).</p